{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T07:35:20Z","timestamp":1769240120193,"version":"3.49.0"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2010,7,1]],"date-time":"2010-07-01T00:00:00Z","timestamp":1277942400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Jpn J Ophthalmol"],"published-print":{"date-parts":[[2010,7]]},"DOI":"10.1007\/s10384-010-0810-4","type":"journal-article","created":{"date-parts":[[2010,8,10]],"date-time":"2010-08-10T12:20:49Z","timestamp":1281442849000},"page":"320-324","source":"Crossref","is-referenced-by-count":27,"title":["Intravitreal bevacizumab therapy for idiopathic macular telangiectasia"],"prefix":"10.1007","volume":"54","author":[{"given":"Yoko","family":"Matsumoto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitsuko","family":"Yuzawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,8,11]]},"reference":[{"key":"810_CR1","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1001\/archopht.1982.01030030773010","volume":"100","author":"J.D. Gass","year":"1982","unstructured":"Gass JD, Oyakawa RT. Idiopathic juxtafoveolar retinal telangiectasis. Arch Ophthalmol 1982;100:769\u2013780.","journal-title":"Arch Ophthalmol"},{"key":"810_CR2","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1016\/S0161-6420(93)31447-8","volume":"100","author":"J.D.M. Gass","year":"1993","unstructured":"Gass JDM, Blodi BA. Idiopathic juxtafoveolar retinal telangiectasis: update of classification and follow-up study. Ophthalmology 1993;100:1536\u20131546.","journal-title":"Ophthalmology"},{"key":"810_CR3","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1001\/archopht.124.4.450","volume":"124","author":"L.A. Yannuzzi","year":"2006","unstructured":"Yannuzzi LA, Bardal AMC, Freund KB, Chen KJ, Eandi CM, Blodi B. Idiopathic macular telangiectasia. Arch Ophthamol 2006;124:450\u2013460.","journal-title":"Arch Ophthamol"},{"key":"810_CR4","first-page":"4593","volume":"57","author":"L.G. Presta","year":"1997","unstructured":"Presta LG, Chen H, O\u2019Connor SJ, et al. Humanization of an antivascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 1997;57:4593\u20134599.","journal-title":"Cancer Res"},{"key":"810_CR5","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1159\/000088479","volume":"69","author":"N. Ferrara","year":"2005","unstructured":"Ferrara N. VEGF as a therapeutic target in cancer. Oncology 2005;69:11\u201316.","journal-title":"Oncology"},{"key":"810_CR6","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1097\/IAE.0b013e31818ba9de","volume":"29","author":"J.L. Kovach","year":"2009","unstructured":"Kovach JL, Rosenfeld PJ. Bevacizumab (Avastin) therapy for idiopathic macular telangiectasia type II. Retina 2009;29:27\u201332.","journal-title":"Retina"},{"key":"810_CR7","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1136\/bjo.2007.129627","volume":"92","author":"P. Charbel Issa","year":"2007","unstructured":"Charbel Issa P, Finger RP, Holtz FG, Scholl HP. Eighteen-months follow up of intravitreal bevacizumab in type 2 idiopathic macular telangiectasia. Br J Ophthalmol 2007;92:941\u2013945.","journal-title":"Br J Ophthalmol"},{"key":"810_CR8","doi-asserted-by":"crossref","first-page":"164","DOI":"10.3928\/15428877-20070301-15","volume":"38","author":"S.J. Moon","year":"2007","unstructured":"Moon SJ, Berger AS, Misch DM. Intravitreal bevacizumab for macular edema from idiopathic juxtafoveal retinal telangiectasis. Ophthalmol Surg Lasers Imaging 2007;38:164\u2013166.","journal-title":"Ophthalmol Surg Lasers Imaging"},{"key":"810_CR9","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1007\/s00417-008-0795-6","volume":"246","author":"M.A. Gamulescu","year":"2008","unstructured":"Gamulescu MA, Walter A, Sachs H, Helbig H. Bevacizumab in the treatment of idiopathic macular telangiectasia. Graefes Arch Clin Ophthalmol 2008;246:1189\u20131193.","journal-title":"Graefes Arch Clin Ophthalmol"},{"key":"810_CR10","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1016\/S0161-6420(97)30019-0","volume":"104","author":"D.W. Park","year":"1997","unstructured":"Park DW, Schatz H, McDonald HR, Johnson RN. Grid laser photocoagulation for macular edema in bilateral juxtafoveal telangiectasis. Ophthalmology 1997;104:1838\u20131846.","journal-title":"Ophthalmology"},{"key":"810_CR11","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1177\/112067210601600508","volume":"16","author":"M. Cakir","year":"2006","unstructured":"Cakir M, Kapran Z, Basar D, Utine CA, Eroglu F, Perente I. Optical coherence tomography evaluation of macular edema after intravitreal triamcinolone acetonide in patients with parafoveal telangiectasis. Euro J Ophthalmol 2006;16:711\u2013717.","journal-title":"Euro J Ophthalmol"},{"key":"810_CR12","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1097\/01.iae.0000244262.91018.4d","volume":"26","author":"C.M. Eandi","year":"2006","unstructured":"Eandi CM, Ober MD, Freund KB, et al. Anecortave acetate for the treatment of idiopathic perifoveal telangiectasia: a pilot study. Retina 2006;26:780\u2013785.","journal-title":"Retina"},{"key":"810_CR13","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1007\/s00417-006-0468-2","volume":"245","author":"R. Jorge","year":"2007","unstructured":"Jorge R, Costa RA, Calucci D, Scott IU. Intravitreal bevacizumab (Avastin) associated with the regression of subretinal neovascularization in idiopathic juxtafoveolar retinal telangiectasis. Graefes Arch Clin Ophthalmol 2007;245:1045\u20131048.","journal-title":"Graefes Arch Clin Ophthalmol"}],"container-title":["Japanese Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10384-010-0810-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10384-010-0810-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10384-010-0810-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,10]],"date-time":"2020-06-10T05:48:08Z","timestamp":1591768088000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10384-010-0810-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,7]]},"references-count":13,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2010,7]]}},"alternative-id":["810"],"URL":"https:\/\/doi.org\/10.1007\/s10384-010-0810-4","relation":{},"ISSN":["0021-5155","1613-2246"],"issn-type":[{"value":"0021-5155","type":"print"},{"value":"1613-2246","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,7]]}}}